Lissa Trocin’s Post

Nature: Bispecific antibodies, against the transferrin receptor (highly expressed in cancer) and cancer membrane proteins, trigger co-internalisation and co-degradation. In this study they were made to target EGFR, PD-L1, and CD20, and killed drug-resistant cancer lines. They represent a promising new family of bifunctional antibodies for precise manipulation of membrane proteins and targeted cancer therapy. https://lnkd.in/e4r9gUbh #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #innovation #technology

Intestine Cancer Therapeutics Global Market Report 2024 . It will grow from $12.8 billion in 2023 to $14 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to advancements in medical research, increased cancer incidence, chemotherapy and radiation therapies, screening and early detection initiatives, genetic and biomarker discoveries. . The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.36 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. . Read More @ https://lnkd.in/g5rEgXd3 . #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

ADCs are a cutting-edge form of targeted cancer therapy that combines monoclonal antibodies with potent drugs. They target specific markers on cancer cells and deliver the drug directly to them. Advancements in antibody engineering and linkers are improving the design of these ADCs for increased efficacy and reduced side effects. What you will learn about: • ADCs and monoclonal antibodies (mAbs) • The manufacturing process • Hazard assessments and protective measures Download this complimentary Expert Insights eBook today! ➡️https://ow.ly/RBUg50TufhE #ADC #conjugates #antigens #cancer #cytotoxic #mAbs #antibodies

In a study funded by our division, Meisam Bagheri, Ph.D., Todd Miller, PhD, Diwakar Pattabiraman, et al. found that eribulin (an FDA-approved chemotherapeutic drug) induces chromatin remodeling to reverse epithelial to mesenchymal transition and sensitizes cancer cells to other chemotherapies in preclinical models of triple-negative #BreastCancer. https://lnkd.in/erd5cpTu

Prostate cancer is the second most common cancer in men globally, with over 1.4 million cases reported in 2020. Early-stage survival rates are high, but significantly decline in advanced stages, highlighting the need for more effective treatments. A recent study using our TRC research chemicals identified the enzyme 2,4-dienoyl CoA reductase 2 (DECR2) as a promising therapeutic target. When combined with standard androgen receptor inhibitors, depletion of the DECR2 enzyme showed potential in treating preclinical models of castration-resistant prostate cancer. Read the full study in the British Journal of Cancer: https://okt.to/pjxGds 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/QlS3mI #ProstateCancer #oncology #oncologyresearch #ResearchChemicals

Advancing a first-in-class AI-enabled cancer drug. A new article from Diana Spencer in Drug Discovery World looks at our REC-1245 program, a potentially first-in-class small molecule that recently received FDA IND clearance for a Phase 1/2 clinical trial for biomarker-enriched solid tumors and lymphoma. ▪ She writes: “Recursion identified the novel regulatory role of RBM39 associated with CDK12 using its maps of biology and first reported this relationship in early 2023, and notes that “preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.” ▪ Chris Gibson says: “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological and chemical relationships across our maps of biology, we identified RMB39 as a novel target that looks functionally similar to the well-known but hard to drug target CDK12. We also identified and optimized small molecules that target RBM39 without directly impacting CDK12 or CDK13 using these same AI-enabled maps.” 👉 Read more: https://lnkd.in/ePy9XY5S #ai #clinicaltrials #techbio #cancer #tumor #cdk12 #rbm39

Prostate cancer is the second most common cancer in men globally, with over 1.4 million cases reported in 2020. Early-stage survival rates are high, but significantly decline in advanced stages, highlighting the need for more effective treatments. A recent study using our TRC research chemicals identified the enzyme 2,4-dienoyl CoA reductase 2 (DECR2) as a promising therapeutic target. When combined with standard androgen receptor inhibitors, depletion of the DECR2 enzyme showed potential in treating preclinical models of castration-resistant prostate cancer. Read the full study in the British Journal of Cancer: https://okt.to/AXjC1Z 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/vn52O1 #ProstateCancer #oncology #oncologyresearch #ResearchChemicals

📣 Exciting times ahead in the realm of prostate cancer treatment! 👨🔬👩🔬 As we explore novel and emerging therapies, the future outlook appears promising. From targeted immunotherapies to precision medicine approaches, 📄 the landscape of prostate cancer care is rapidly evolving. Stay tuned for groundbreaking advancements that hold the potential to revolutionize patient outcomes. Together, we're shaping the future of prostate cancer treatment. For more informative updates, visit 🌐 www.vyuhpharma.com #PharmaRegulations #RegulatoryTrends #WhitePaper #PharmaceuticalIndustry #pharmanews #pharmaceutical #healthcare  #pharmaceuticalindustry #ProstateCancer #Innovation #MedicalAdvancements #CancerResearch #PrecisionMedicine #Immunotherapy #oncology

Prostate cancer is the second most common cancer in men globally, with over 1.4 million cases reported in 2020. Early-stage survival rates are high, but significantly decline in advanced stages, highlighting the need for more effective treatments. A recent study using our TRC research chemicals identified the enzyme 2,4-dienoyl CoA reductase 2 (DECR2) as a promising therapeutic target. When combined with standard androgen receptor inhibitors, depletion of the DECR2 enzyme showed potential in treating preclinical models of castration-resistant prostate cancer. Read the full study in the British Journal of Cancer: https://okt.to/5OARDX 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/aOlMAb #ProstateCancer #oncology #oncologyresearch #ResearchChemicals

📢 Genmab's $18bn ADC Acquisition to Revolutionize Cancer Treatment 💥 Genmab is acquiring ProfoundBio for $1.8bn to expand its pipeline of antibody-drug conjugate therapies. 💊 The deal includes three ADCs in clinical trials, including rinatabart sesutecan, an ADC targeting ovarian and other cancers. 🏭 The acquisition is expected to close in the first half of the year, subject to regulatory approvals. 🚀 Genmab aims to accelerate the development of innovative antibody therapies for cancer patients. #BioprocessUpdates #Genmab #ProfoundBio #ADCpipeline #antibodydrugconjugate #therapies #clinicaltrials #rinatabartsesutecan #ovariancancer #cancer #acquisition #regulatoryapprovals #innovativeantibodytherapies #cancerpatients #biotech #pharmaceuticals ▷ Read the full article here: 📎 https://lnkd.in/d6RUXyFs